Therapeutic uses of BR43X2 soluble receptors
    7.
    发明公开
    Therapeutic uses of BR43X2 soluble receptors 审中-公开
    Verfahren zurapeutischen Verwendung vonlöslichenrezeptoren BR43X2

    公开(公告)号:EP2256199A1

    公开(公告)日:2010-12-01

    申请号:EP10175468.7

    申请日:2000-01-07

    摘要: There is provided a fusion protein consisting of a first portion and a second portion joined by a peptide bond, wherein said first portion consists of an amino acid sequence selected from: (i) amino acid residues 25-104 of SEQ ID NO: 6; (ii) amino acid residues 34-66 of SEQ ID NO: 6; (iii) amino acid residues 71-104 of SEQ ID NO: 6; and (iv) amino acid residues 34-66 and 71-104 of SEQ ID NO: 6; and said second portion is an immunoglobulin heavy chain constant region. There is also provided an antibody or antibody fragment that specifically binds to a polypeptide selected from SEQ ID NO: 59 or SEQ ID N: 60. There is also provided an antibody or antibody fragment that specifically binds to a ztnf4 polypeptide, for use in treating systemic lupus erythematosus in a mammal.

    摘要翻译: 提供了由肽键连接的第一部分和第二部分组成的融合蛋白,其中所述第一部分由选自以下的氨基酸序列组成:(i)SEQ ID NO:6的氨基酸残基25-104; (ii)SEQ ID NO:6的氨基酸残基34-66; (iii)SEQ ID NO:6的氨基酸残基71-104; 和(iv)SEQ ID NO:6的氨基酸残基34-66和71-104; 而第二部分是免疫球蛋白重链恒定区。 还提供了特异性结合选自SEQ ID NO:59或SEQ ID NO:60的多肽的抗体或抗体片段。还提供了特异性结合ztnf4多肽的抗体或抗体片段,用于治疗 系统性红斑狼疮在哺乳动物中。

    Therapeutic uses of BR43X2 soluble receptors
    9.
    发明公开
    Therapeutic uses of BR43X2 soluble receptors 有权
    BR43X2可溶性受体的治疗用途

    公开(公告)号:EP1642972A1

    公开(公告)日:2006-04-05

    申请号:EP05018984.4

    申请日:2000-01-07

    摘要: Soluble, secreted tumor necrosis factor receptor polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed. The polypeptides comprise one cysteine-rich repeat that is homologous to other tumor necrosis factor receptors, such as transmembrane activator and CAML-interactor (TACI). The polypeptides may be used for detecting ligands, agonists and antagonists. The polypeptides may also be used in methods that modulate B cell activation.

    摘要翻译: 公开了可溶性分泌的肿瘤坏死因子受体多肽,编码该多肽的多核苷酸以及相关的组合物和方法。 多肽包含一种与其他肿瘤坏死因子受体如跨膜激活剂和CAML相互作用剂(TACI)同源的富含半胱氨酸的重复序列。 多肽可用于检测配体,激动剂和拮抗剂。 多肽也可用于调节B细胞活化的方法中。